In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 7, 2005, Pages 3040-3045

  Fujikawa, Katsuko ^a   Chiba, Megumi ^a   Tanaka, Mayumi ^a   Sato, Kenichi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAMASE; CEFACLOR; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINAFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DX 619; GARENOXACIN; GATIFLOXACIN; HABEKACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; METICILLIN; METRONIDAZOLE; MINOCYCLINE; MOXIFLOXACIN; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEROIDES FRAGILIS; CITROBACTER; CLOSTRIDIUM DIFFICILE; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG STRUCTURE; ENTEROBACTER; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS GALLINARUM; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NEISSERIA GONORRHOEAE; NONHUMAN; PEPTOSTREPTOCOCCUS; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SALMONELLA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 21444435346     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.7.3040-3045.2005     Document Type: Article

References (22)

1. Bell, J. M., and J. D. Turnidge. 2002. High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY Antimicrobial Surveillance Program, 1998-1999. Antimicrob. Agents Chemother. 46:879-881.
2. Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Dowries, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, S. K. Fridkin, and the Vancomycin-Resistant Staphylococcus aureus Investigative Team. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347.
3. Clemett, D., and A. Markham. 2000. Linezolid. Drugs 59:815-827.
4. Diekema, D. J., B. J. BootsMiller, T. E. Vaughn, R. F. Woolson, J. W. Yankey, E. J. Ernst, S. D. Flach, M. M. Ward, C. L. J. Franciscus, M. A. Pfaller, and B. N. Doebbeling. 2004. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin. Infect. Dis. 38:78-85.
5. Georgopapadakou, N. H. 2002. Infectious disease 2001: drug resistance, new drugs. Drug Resist. Update 5:181-191.
6. Herold, B. C., L. C. Immergluck, M. C. Maranan, D. S. Lauderdale, R. E. Gaskin, S. Boyle-Vavra, C. D. Leitch, and R. S. Daum. 1998. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identifiable predisposing risk. JAMA 279:593-598.
7. Japan Society of Chemotherapy. 1981. Method for the determination of minimum inhibitory concentration (MIC) of aerobic bacteria by agar dilution method. Chemotherapy (Tokyo) 29:76-79. (In Japanese.)
8. Jones, M. E., R. S. Blosser-Middleton, C. Thornsberry, J. A. Karlowsky, and D. F. Sahm. 2003. The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002. Diagn. Microbiol. Infect. Dis. 47:579-586.
9. Kacica, M. 2004. Vancomycin-resistant Staphylococcus aureus-New York, 2004. Morb. Mortal. Wkly. Rep. 53:322-323.
10. Mathai, D., R. N. Jones, M. A. Pfaller, and the SENTRY Participant Group North America. 2001. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn. Microbiol. Infect. Dis. 40:129-136.
11. National Committee for Clinical Laboratory Standards. 2001. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 5th ed. M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial susceptibility testing; 13th informational supplements. M100-S13. National Committee for Clinical Laboratory Standards, Wayne, Pa.
13. Nilgate, S., P. Nunthapisud, and A. Chongthaleong. 2003. Vancomycin-resistant enterococci in King Chulalongkorn Memorial Hospital: a 5-year study. J. Med. Assoc. Thai. 86(Suppl. 2):S224-S229.
14. NNIS System. 2003. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Control 31:481-498.
15. Rahim, S., S. K. Pillai, H. S. Gold, L. Venkataraman, K. Inglima, and R. A. Press. 2003. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin. Infect. Dis. 36:E146-E148.
16. Sahm, D. F., M. E. Jones, M. L. Hickey, D. R. Diakun, S. V. Mani, and C. Thomsberry. 2000. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. J. Antimicrob. Chemother. 45:457-466.
17. Schmitz, F. J., A. C. Fluit, A. Brisse, J. Verhoef, K. Kohrer, and D. Milatovic. 1999. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol. Med. Microbiol. 26:281-287.
18. Tenover, F. C., L. M. Weigel, P. C. Appelbaum, L. K. McDougal, J. Chaitram, S. McAllister, N. Clark, G. Killgore, C. M. O'Hara, L. Jevitt, J. B. Patel, and B. Bozdogan. 2004. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48:275-280.
19. Watanakunakorn, C. 1981. The antibacterial action of vancomycin. Rev. Infect. Dis. 3:S210-S215.
20. Yamaguchi, K., A. Ohno, F. Kashitani, M. Iwata, and the Levofloxacin Surveillance Group. 2003. Activity of antimicrobial agents against 8,474 clinical isolates obtained from 37 medical institutions during 2000 in Japan. Jpn. J. Antibiot. 56:5-24.
21. Yamaguchi, K., A. Ohno, F. Kashitani, M. Iwata, and the Levofloxacin Surveillance Group. 2005. In vitro susceptibilities to levofloxacin and various antimicrobial agents of 11,475 clinical isolates obtained from 52 centers in 2002. Jpn. J. Antibiot. 58:17-44.
22. Zurenko, G. E., B. H. Yagi, R. D. Schaadt, J. W. Allison, J. O. Kilburn, S. E. Glickman, D. K. Hutchinson, M. R. Barbachyn, and S. J. Brickner. 1996. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40:839-845.